Immatics N.V.

NASDAQ:IMTX

6.85 (USD) • At close December 20, 2024
Bedrijfsnaam Immatics N.V.
Symbool IMTX
Munteenheid USD
Prijs 6.85
Beurswaarde 817,588,600
Dividendpercentage 0%
52-weken bereik 6.68 - 13.77
Industrie Biotechnology
Sector Healthcare
CEO Dr. Harpreet Singh Ph.D.
Website https://www.immatics.com

An error occurred while fetching data.

Over Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell

Vergelijkbare Aandelen

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

11.4 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

0.635 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

1.76 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

3.14 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

25.86 USD

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

15.48 USD

Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

CARA

0.423 USD

Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NRIX

19.83 USD

908 Devices Inc. logo

908 Devices Inc.

MASS

2.06 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)